Prospective analysis of the association between skeletal‑related events and quality of life in patients with advanced lung cancer (CSP‑HOR13)

Kunikane,Hiroshi; Yokota,Isao; Katakami,Nobuyuki; Takeda,Koji; Takayama,Koichi; Sawa,Toshiyuki; Saito,Hiroshi; Harada,Masao; Yokota,Soichiro; Ando,Kiyoshi; Saito,Yuko; Ohashi,Yasuo; Eguchi,Kenji

doi:10.3892/ol.2018.9680

Prospective analysis of the association between skeletal‑related events and quality of life in patients with advanced lung cancer (CSP‑HOR13)

Authors:
- Hiroshi Kunikane
- Isao Yokota
- Nobuyuki Katakami
- Koji Takeda
- Koichi Takayama
- Toshiyuki Sawa
- Hiroshi Saito
- Masao Harada
- Soichiro Yokota
- Kiyoshi Ando
- Yuko Saito
- Yasuo Ohashi
- Kenji Eguchi
View Affiliations

Affiliations: Department of Palliative Medicine, Yokohama Municipal Citizen's Hospital, Yokohama, Kanagawa 240‑8555, Japan, Department of Biostatistics, Kyoto Prefectural University of Medicine, Kyoto, Kyoto 602‑8566, Japan, Division of Integrated Oncology, Institute of Biomedical Research and Innovation, Kobe, Hyōgo 650‑0047, Japan, Division of Medical Oncology, Osaka City General Hospital, Osaka, Osaka 534‑0021, Japan, Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Kyoto 602‑8566, Japan, Division of Respiratory Medicine and Oncology, Gifu Municipal Hospital, Gifu, Gifu 500‑8513, Japan, Department of Respiratory Medicine, Aichi Cancer Center Aichi Hospital, Okazaki, Aichi 444‑0011, Japan, Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido 003‑0804, Japan, Department of Respiratory Medicine, Toneyama National Hospital, Toyonaka, Osaka 560‑0045, Japan, Division of Hematology/Oncology, Tokai University School of Medicine, Isehara, Kanagawa 259‑1193, Japan, Clinical Trial Coordination Office, Shizuoka Cancer Center, Shizuoka, Shizuoka 411‑8777, Japan, Department of Integrated Science and Engineering for Sustainable Society, Chuo University, Tokyo 112‑8551, Japan, Medical Oncology, Teikyo University School of Medicine, Tokyo 173‑8606, Japan
Published online on: November 9, 2018 https://doi.org/10.3892/ol.2018.9680
Pages: 1320-1326

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A prospective study has previously reported on the incidence of bone metastasis (BM) and skeletal‑related events (SREs) in patients with advanced lung cancer. The aim of the present study was to prospectively investigate how the quality of life (QOL) of patients with advanced lung cancer was affected by SREs. Patients with stage IIIB or IV non‑small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) at any stage were followed up every four weeks to determine if they had developed SREs. QOL questionnaires were conducted at enrollment, at 3‑ and 12‑months later and at 1 month after the onset of SREs, using QOL scores including the EuroQOL‑5 Dimension (EQ‑5D), Functional Assessment of Cancer Therapy‑General (FACT‑G) and activities of daily living (ADL) scores obtained by the Barthel Index. A total of 274 patients were enrolled in the study. At enrollment the EQ‑5D and Barthel Index scores were lower in patients with SREs compared with patients without SREs. A chronological analysis revealed no statistically significant changes in either QOL or ADL in any of the patients. For 14 patients in whom QOL data was collected following the onset of SREs, the evaluation undertaken on the four subscales of the FACT‑G revealed a significant decline in emotional functioning following the onset of SREs.

View Figures

View References

1	Stinchcombe TE, Lee CB and Socinski MA: Current aproaches to advanced-stage non-small-cel lung cancer: First-line therapy in patients with a good functional status. Clin Lung Cancer. 7 Suppl 4:S111–S117. 2006. View Article : Google Scholar : PubMed/NCBI
2	Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 12:6243s–6249s. 2006. View Article : Google Scholar : PubMed/NCBI
3	Sugiura H, Yamada K, Sugiura T, Hida T and Mitsudomi T: Predictors of survival in patients with bone metastasis of lung cancer. Clin Orthop Relat Res. 466:729–736. 2008. View Article : Google Scholar : PubMed/NCBI
4	Botteman M, Barghout V, Stephens J, Hay J, Brandman J and Aapro M: Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol. 17:1072–1082. 2006. View Article : Google Scholar : PubMed/NCBI
5	Tsuya A, Kurata T, Tamura K and Fukuoka M: Skeletal metastases in non-small cell lung cancer: A retrospective study. Lung Cancer. 57:229–232. 2007. View Article : Google Scholar : PubMed/NCBI
6	Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, de Souza P, Zheng M, Urbanowitz G, et al: Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double blind, randomized trial-the zoledoronic acid lung cancer and other solid tumors study group. J Clin Oncol. 21:3150–3157. 2003. View Article : Google Scholar : PubMed/NCBI
7	Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, et al: Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double blind, placebo-controlled trial. Cancer. 100:2613–2221. 2004. View Article : Google Scholar : PubMed/NCBI
8	Ishiwata T, Hirose T, Hirama M, Miura K, Iwakami S, Tominaga S, Adachi M and Takahashi K: A feasibility study of zoledronic acid combined with carboplatin/nedaplatin plus paclitaxel in patients with non-small cell lung cancer with bone metastases. Tumori. 97:568–572. 2011. View Article : Google Scholar : PubMed/NCBI
9	Addeo R, Nocera V, Faiola V, Vincenzi B, Ferraro G, Montella L, Guarrasi R, Rossi E, Cennamo G, Tonini G, et al: Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: A single-institution report. Support Care Cancer. 16:209–214. 2008. View Article : Google Scholar : PubMed/NCBI
10	Facchini G, Caraglier M, Santini D, Nasti G, Ottaiano A, Striano S, Maiolino P, Ruberto M, Fiore F, Tonini G, et al: The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE). J Exp Clin Cancer Res. 26:307–312. 2007.PubMed/NCBI
11	Katakami N, Kunikane H, Takeda K, Takayama K, Sawa T, Saito H, Harada M, Yokota S, Ando K, Saito Y, et al: Prospective study on the incidence of bone metastasis (BM) and skeletal-related events (SREs) in patients (pts) with stage IIIB and IV lung cancer-CSP-HOR 13. J Thorac Oncol. 9:231–238. 2014. View Article : Google Scholar : PubMed/NCBI
12	Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, Hamashima C, Hisashige A and Tamura M: Estimating an EQ-5D population value set: The case of Japan. Health Econ. 11:341–353. 2002. View Article : Google Scholar : PubMed/NCBI
13	Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan E and Bonomi P: Reliability and validity of the functional assessment of cancer therapy-lung (FACT-L) quality of life instrument. Lung Cancer. 12:199–220. 1995. View Article : Google Scholar : PubMed/NCBI
14	Mahoney FI and Barthel DW: Functional evaluation; the Barthel Index. Md State Med J. 14:61–65. 1965.PubMed/NCBI
15	Kretzschmar A, Wiegel T, AI-Batran SE, Hinrichs HF, Kindler M, Steck T, Illiger HJ, Heinemann V, Schmidt K, Haus U, et al: Rapid and sustained influence of intravenous zoledronic acid on course of pain and analgesics consumption in patients with cancer with bone metastases: A multicenter open-label study over 1 year. Support Cancer Ther. 4:203–210. 2007. View Article : Google Scholar : PubMed/NCBI
16	Mystakidou K, Katsouda E, Parpa E, Kouskouni E, Chondros C, Tsiatas ML, Galanos A and Vlahos L: A prospective randomized controlled clinical trial of zoledronic acid for bone metastases. Am J Hosp Palliat Care. 23:41–50. 2006. View Article : Google Scholar : PubMed/NCBI
17	Chow E and Bottomley A: Understanding the EORTC QLQ-BM22, the module for patients with bone metastases. Expert Rev Pharmacoecon Outcomes Res. 9:461–465. 2009. View Article : Google Scholar : PubMed/NCBI
18	Koizumi M, Yoshimoto M, Kasumi F, Iwase T and Ogata E: Post-operative breast cancer patients diagnosed with skeletal metastasis without bone pain had fewer skeletal-related events and deaths than these with bone pain. BMC Cancer. 10:4232010. View Article : Google Scholar : PubMed/NCBI
19	Bezjak A, Lee CW, Ding K, Brundage M, Winton T, Graham B, Whitehead M, Johnson DH, Livingston RB, Seymour L and Shepherd FA: Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: Result from a randomized trial, JBR. 10. J Clin Oncol. 26:5052–5059. 2008. View Article : Google Scholar : PubMed/NCBI
20	Mills M, Murray LJ, Johnston BT, Cardwell C and Donnelly M: Does a patient-held quality-of-life diary benefit patients with inoperable lung cancer? J Clin Oncol. 27:70–77. 2009. View Article : Google Scholar : PubMed/NCBI
21	Efficace F, Bottomley A, Smit EF, Lianes P, Legrand C, Debruyne C, Schramel F, Smit HJ, Gaafar R, Biesma B, et al: Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol. 17:1698–1704. 2006. View Article : Google Scholar : PubMed/NCBI
22	Belani CP, Brodowicz T, Ciuleanu TE, Krzakowski M, Yang SH, Franke F, Cucevic B, Madhavan J, Santoro A, Ramlau R, et al: Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3H-MC-JMEN): Result from a randomised, double-blind, phase 3 study. Lancet Oncol. 13:292–299. 2012. View Article : Google Scholar : PubMed/NCBI